{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:09Z","timestamp":1789745409882,"version":"4.0.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clinthera.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T09:42:35Z","timestamp":1714556555000},"page":"439-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-084X","authenticated-orcid":false,"given":"Albert","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.03.005_bib0001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0002","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0003","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","article-title":"Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment","volume":"37","author":"Gisslinger","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0004","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2V617F allele burden in polycythemia vera: burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","article-title":"A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: finding from a phase 2 study in Chinese patients with polycythemia vera","volume":"12","author":"Jin","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1109866","article-title":"An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future","volume":"13","author":"Qin","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0007","article-title":"Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways","volume":"11","author":"Mazewsky","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0008","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1089\/10799900260442511","article-title":"Direct evidence that IFN-beta functions as a tumor-suppressor protein","volume":"22","author":"Kaynor","year":"2002","journal-title":"J Interferon cytokine Res"},{"key":"10.1016\/j.clinthera.2024.03.005_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1173467","article-title":"An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1","volume":"13","author":"Qin","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T08:41:59Z","timestamp":1719477719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0149291824000729"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}